In certain subsets of AML, such as those driven by the fusion oncoproteins AML1-ETO or PML-RARα, the expression of key HR proteins (including RAD51, ATM, BRCA1, and BRCA2) is suppressed, producing sensitivity to PARP inhibition [131]. This evidence concerns the gene ATM and acute myeloid leukemia.